Verrica Pharmaceuticals (FRA:1NE0) Total Liabilities: €19.66 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1NE0 Verrica Pharmaceuticals Inc FRA:1NE0
44 GF Score
Price €4.64
GF Value €12.17
! 2 Warning Signs
View Full Analysis

What is Verrica Pharmaceuticals Total Liabilities?

Verrica Pharmaceuticals FRA:1NE0 +1.20% 44 Total Liabilities is €19.66 Mil as of Mar. 2026. GuruFocus rates FRA:1NE0 with a GF Score™ of 44/100 and a GF Value™ of €12.17. The stock has 2 warning signs investors should review.

Verrica Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 was €19.66 Mil.

Verrica Pharmaceuticals's quarterly Total Liabilities declined from Sep. 2025 (€49.36 Mil) to Dec. 2025 (€19.12 Mil) but then increased from Dec. 2025 (€19.12 Mil) to Mar. 2026 (€19.66 Mil).

Verrica Pharmaceuticals's annual Total Liabilities increased from Dec. 2023 (€56.70 Mil) to Dec. 2024 (€61.11 Mil) but then declined from Dec. 2024 (€61.11 Mil) to Dec. 2025 (€19.12 Mil).

Verrica Pharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for Verrica Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Verrica Pharmaceuticals Total Liabilities Chart

Verrica Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.06 4.43 56.70 61.11 19.12

Verrica Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 56.20 49.06 49.36 19.12 19.66
FRA:1NE0
44GF Score
Verrica Pharmaceuticals Inc FRA:1NE0
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Verrica Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Verrica Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=14.037+(0.756+4.326
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=19.12

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=40.25-21.131
=19.12

Verrica Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=14.029+(0.604+5.029
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=19.66

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=33.55-13.888
=19.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €19.66 Mil mean?
Verrica Pharmaceuticals (FRA:1NE0) has a Total Liabilities of €19.66 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Verrica Pharmaceuticals and its competitors.
Is Verrica Pharmaceuticals' Total Liabilities too high?
Verrica Pharmaceuticals' current Total Liabilities is €19.66 Mil. Overall, Verrica Pharmaceuticals has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Verrica Pharmaceuticals' Total Liabilities compare to HRTX and RLYB?
Verrica Pharmaceuticals' Total Liabilities of €19.66 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Verrica Pharmaceuticals and its competitors. Verrica Pharmaceuticals's current Total Liabilities is €19.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verrica Pharmaceuticals stock overvalued right now?
Verrica Pharmaceuticals (FRA:1NE0) has a current Total Liabilities of €19.66 Mil. The stock's GF Value™ is €12.17, compared to a current price of €4.64 — trading 61.9% below its estimated fair value. The current Total Liabilities is €19.66 Mil. Verrica Pharmaceuticals' overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Verrica Pharmaceuticals (FRA:1NE0), the current Total Liabilities is €19.66 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Verrica Pharmaceuticals (FRA:1NE0) Overvalued in 2026?

Based on GuruFocus' analysis, Verrica Pharmaceuticals stock appears to be undervalued. The current stock price of €4.64 is trading 61.9% below its estimated GF Value™ of €12.17.

Key valuation signals for FRA:1NE0:

  • Total Liabilities: €19.66 Mil
  • GF Value™: €12.17 vs. price of €4.64 (61.9% below fair value)
  • GF Score™: 44/100 with 2 warning signs

No single metric tells the full story. See the FRA:1NE0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Verrica Pharmaceuticals Business Description

Other Exchanges VRCA:USA
Address 44 West Gay Street, Suite 400, West Chester, PA, USA, 19380
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
44GF Score

Get the complete analysis for FRA:1NE0

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.64
Price
€12.17
GF Value